Timmerman Report is an independently-owned subscription publication that provides timely, in-depth biotech news and analysis. It’s for anyone who seeks to understand new drug development, diagnostics, genomics, and other technologies that are changing medicine.
I’m looking for the true innovations, the emerging trends, the market forces, and the characters at work. Because I’ve been covering the industry for more than a decade—through two busts and one and a half booms—I bring context to stories that few can match. Readers should expect big picture perspective, and a steady drumbeat of news, features, and original commentary.
This type of in-depth reporting will help prepare you for your next big meeting, find a partner, jump on an investment opportunity, hire an up-and-comer, get to know the people you work with, or land a job.
My goal is to write accessibly for all of you: in a way that specialized readers can appreciate and lay readers can understand. It’s the sort of clear, probing and contextual journalism that never goes out of style.
I look forward to serving you, the biotech reader, for years to come.
I focus on science, technology, medical evidence, regulatory issues and business strategy. I study how these things affect all kinds of organizations—everything from startups on their first $1 million to academic institutions to established companies. Subjects range from cancer to Alzheimer’s to genetic diseases and conditions that scientists are only beginning to adequately define.
Yes. This license grants companies with five or more subscribers the right to share copyrighted Timmerman Report content in-house. Groups can get a 10 percent discount off the regular rate of $149 per subscriber per year. If you are interested in a corporate license, please send me a list of all the names and emails of people in your organization that would like to subscribe. Email me at firstname.lastname@example.org.
About 2-3 stories per week on average.
You’ll get an e-mail as soon as the story is published. Story links will also be posted on Twitter: @TimmermanReport
Memberful is the paywall software provider, and Stripe is the payment processing vendor.
No. As long as your web browser allows cookies, you will be automatically signed in every time you come to Timmerman Report. If you want to sign in on a second device, like a tablet or smartphone, then you will have to sign in once on that device, too.
Luke Timmerman sets the standard for excellence in biotech journalism. His brand of independent reporting is essential for our industry.
Timmerman is always ahead of the game.
Timmerman Report has been fantastic for our students and postdocs here at MIT’s Koch Institute, based on overwhelmingly positive feedback. As many of our trainees move on to diverse positions within the biotech ecosystem, TR provides them with invaluable working knowledge, insight, and language beyond academia.
Today’s biotech social media is easy to obtain, but is a firehose of data, information, and speculation. The savvy professional needs less noise and more actionable signal. Luke Timmerman finds and writes about that signal.
Luke’s ability to blend the implications of science with the exigencies of business creates an idiosyncratic and insightful read.
Meryl Schenker Photography
Luke Timmerman is an award-winning journalist who has been covering biotechnology since 2001. Luke has written about the industry for a regional mass media publication (The Seattle Times), a global financial audience (Bloomberg News), and an online startup (Xconomy). He is a contributing writer for Forbes, and the co-host of Signal, a biotech podcast produced by STAT. His first book, “Hood: Trailblazer of the Genomics Age” was named a “must-read” science book by Forbes in 2016.
Luke was named one of the 100 Most Influential People in Biotechnology by Scientific American Worldview in 2015. He has won a number of reporting prizes, including the Scripps Howard National Journalism Award, the Association of Health Care Journalists Award, and has twice been named a finalist for the Gerald Loeb Award, the highest honor in business journalism. Luke is a regular commentator on KUOW, Seattle’s public radio station, and is a frequent speaker and moderator at biotech industry events. Luke earned a bachelor’s degree in journalism from the University of Wisconsin-Madison in 1997, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
In his spare time, Luke enjoys running, mountaineering (hence, the mountain logo), fantasy baseball, and watching the Green Bay Packers and Wisconsin Badgers. He lives in Seattle with his wife and daughter. When he’s not banging at his keyboard or hanging around biotech conferences, you can find him running on the Burke-Gilman trail or lugging a heavy backpack up one of Seattle’s notoriously steep hills.